FilingReader Intelligence
SSY Group wins first China approval for MS drug
August 13, 2025 at 05:02 PM UTC•By FilingReader AI
SSY Group Limited announced that its Fampridine drug has been approved for registration by China's National Medical Products Administration as a bulk drug for market preparations. This marks the first such approval for PRC entities.
Fampridine is a potassium channel blocker primarily used to improve walking speed in adults with multiple sclerosis.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
HKEX:2005•Hong Kong Exchange
News Alerts
Get instant email alerts when SSY Group publishes news
Free account required • Unsubscribe anytime